Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | LAVA-051: a novel bispecific T-cell engager for R/R hematological malignancies

Arnon Kater • 9 Jun 2022
EHA 2022
Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Leukemia Multiple Myeloma BiTEs LAVA-051

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses LAVA-051, a novel bispecific T-cell engager being investigated for the treatment of relapsed/refractory hematological malignancies. LAVA-051 engages gamma delta T-cells and has shown clinical effects in chronic lymphocytic leukemia (CLL) and multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Arnon Kater

Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1 1:48
Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1
Arnon Kater • 6 Dec 2025
Epcoritamab in combination with R-CHOP or lenalidomide for Richter’s transformation 1:05
Epcoritamab in combination with R-CHOP or lenalidomide for Richter’s transformation
Arnon Kater • 6 Dec 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease 19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater et al. • 25 Apr 2025
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status 2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
The content of VJHemOnc is intended for healthcare professionals